newsfilter.io
Nov 4, 2026, 4:51 PM ETHealthcare

Summit Therapeutics — Q3 2026 Earnings Summary

SMMTSUMMIT THERAPEUTICS INC
Source

Financial Performance

  • Reported a GAAP net loss of $208.4 million ($0.26 per share) for the third quarter of 2026, compared to a net loss of $231.8 million ($0.31 per share) in the same period of 2025.
  • Reported a Non-GAAP net loss of $160.7 million ($0.20 per share) for the third quarter of 2026, compared to $101.0 million ($0.13 per share) in the prior year period.
  • GAAP operating expenses were $214.6 million for the third quarter of 2026, a decrease from $234.2 million in the prior year, driven by a $83.1 million reduction in stock-based compensation.
  • Non-GAAP operating expenses increased to $166.9 million in the third quarter of 2026 from $103.4 million in the prior year, primarily due to expanded clinical studies and development costs for ivonescimab.
  • GAAP Research and Development (R&D) expenses were $169.1 million for the third quarter of 2026, up from $131.1 million in the prior year, driven by ivonescimab development costs offset by a $16.7 million decrease in stock-based compensation.
  • Non-GAAP R&D expenses were $145.2 million for the third quarter of 2026, compared to $90.5 million in the prior year.
  • GAAP General and Administrative (G&A) expenses were $45.5 million for the third quarter of 2026, down from $103.1 million in the prior year, due to a $66.4 million decrease in stock-based compensation.
  • Non-GAAP G&A expenses were $21.7 million for the third quarter of 2026, up from $12.9 million in the prior year, driven by infrastructure and headcount expansion.
  • Cash and cash equivalents plus short-term investments totaled $629.8 million as of September 30, 2026, compared to $713.4 million as of December 31, 2025.
  • Raised $94.1 million in gross proceeds through the ATM facility during the third quarter of 2026.
  • Net cash used in operating activities was $423.2 million for the nine months ended September 30, 2026, compared to $221.0 million in the prior year period.
  • Net cash provided by financing activities was $330.3 million for the nine months ended September 30, 2026, compared to $43.7 million in the prior year period.

Guidance and Future Outlook

  • The FDA accepted the Biologics License Application (BLA) for ivonescimab in EGFR-mutated non-squamous NSCLC in January 2026, with a PDUFA goal action date of November 14, 2026.
  • Summit plans to host a conference call and webcast following the FDA's action on the BLA.
  • Enrollment for the HARMONi-3 squamous cohort is complete, with the number of PFS events expected to be reached in Q4 2026; an interim OS analysis is planned for the first half of 2027.
  • Enrollment for the HARMONi-3 non-squamous cohort is ongoing, with PFS events expected to be reached in the first half of 2027.
  • HARMONi-7 enrollment is expected to be completed in 2027.
  • HARMONi-GI3 enrollment is expected to complete in Q3 2027.
  • Summit intends to continue expanding the global clinical development program for ivonescimab with additional Phase III studies in settings beyond NSCLC, CRC, UC, RCC, BTC, and HNSCC.

Business Segments and Product Lines

  • Ivonescimab: A novel, potentially first-in-class investigational bispecific antibody combining PD-1 blockade and VEGF inhibition. Over 5,000 patients have been treated in global clinical studies, and over 100,000 patients have been treated commercially in China.
  • HARMONi (NSCLC): The study met its primary PFS endpoint. Updated OS analysis (June 2026) showed a hazard ratio of 0.76 (95% CI: 0.61 – 0.95; nominal p=0.0151) in the global ITT population, with consistent results in the western subgroup.
  • HARMONi-2 (NSCLC): Interim OS data presented at WCLC 2026 showed ivonescimab monotherapy achieved a statistically significant improvement over pembrolizumab with a hazard ratio of 0.73 (95% CI: 0.57, 0.95; p=0.009).
  • HARMONi-GI1 (BTC): Presented at ESMO 2026, ivonescimab plus chemotherapy demonstrated a statistically significant OS improvement versus durvalumab plus chemotherapy with a hazard ratio of 0.75 (95% CI: 0.61, 0.92; p=0.0031).
  • HARMONi-GU1 (Bladder Cancer): Global Phase II/III trial initiated in August 2026 evaluating ivonescimab plus enfortumab vedotin; Phase II site activations and enrollment have begun.
  • SMT112-216 (Kidney Cancer): Global Phase II study initiated in October 2026 for first-line ccRCC, enrolling approximately 100 patients in the U.S. and China.
  • HARMONi-GI3 (Colorectal Cancer): Enrollment is ongoing with a target of 900 patients; enrollment rate has exceeded initial estimates.
  • Collaborations:
    • Entered a clinical trial collaboration with AstraZeneca in September 2026 to evaluate ivonescimab with sonesitatug vedotin (sone-ve) in gastrointestinal cancers.
    • Executed a non-binding MOU in September 2026 with AstraZeneca to conduct future clinical trials combining ivonescimab with multiple AstraZeneca cancer medicines.
    • Announced a collaboration in October 2026 with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab with Datopotamab deruxtecan (Datroway®), starting with a Phase III trial in first-line triple-negative breast cancer.
    • Announced a collaboration with Arcus Biosciences in July 2026 to evaluate ivonescimab with casdatifan in ccRCC.
    • Announced a collaboration with ECOG-ACRIN in October 2026 for the EA2251 study in biliary tract cancer.
    • Ongoing collaborations with Revolution Medicines, GORTEC, and GSK are progressing.
    • Supports over 65 Investigator-Sponsored Trials (ISTs), with 26 actively enrolling.

Market and Competitive Landscape

  • Summit holds exclusive rights to develop and commercialize ivonescimab in North America, South America, Europe, the Middle East, Africa, and Japan; Akeso retains rights for China and other territories.
  • Ivonescimab was initially approved for marketing authorization in China in May 2024.
  • The HARMONi study is the first global Phase III study of an immunotherapy-based regimen to show a statistically significant PFS improvement in EGFR-mutated non-squamous NSCLC.
  • Five Phase III ivonescimab clinical trials have read out to date with positive data: HARMONi (Summit-sponsored), and HARMONi-A, HARMONi-2, HARMONi-6, and HARMONi-GI1 (Akeso-sponsored).
  • No FDA-approved options in the HARMONi setting have previously demonstrated a statistically significant OS benefit.

Risks and Challenges

  • The FDA noted that a statistically significant OS benefit is necessary to support marketing authorization for the HARMONi indication; while the primary OS analysis did not achieve statistical significance, updated analysis showed a positive trend.
  • Clinical trial results may not be predictive of final results, and trial initiation, completion, or data availability may be delayed.
  • The company relies on third parties, including Akeso, for the supply of ivonescimab and contributions to certain combination clinical trials.
  • Dilution to existing stockholders and potential adverse effects on market price may occur from future sales by AstraZeneca or the ATM Program.
  • AstraZeneca holds contractual rights, including third-party acquisition participation, registration rights, and potential conflicts of interest.
  • Forward-looking statements regarding spending, cash runway, and regulatory approvals are subject to various risks including capital market conditions, geopolitical developments, and regulatory uncertainties.

Management Commentary and Tone

  • Robert W. Duggan, Chairman and Co-CEO, stated the quarter marked "meaningful momentum" highlighted by the AstraZeneca investment and expanding collaborations, underscoring "ever growing confidence in ivonescimab's potential."
  • Dr. Maky Zanganeh, President and Co-CEO, expressed encouragement regarding statistically significant OS results from Akeso's studies and noted the global clinical program continues to broaden with new studies in bladder, biliary tract, and kidney cancers.
  • Management believes ivonescimab has a favorable benefit-risk profile in the HARMONi setting given the safety profile and the lack of OS benefit in current approved options.

Analyst Questions and Answers

  • No specific analyst questions and answers were included in the provided press release text.

Other Key Points

  • AstraZeneca completed a $2.0 billion strategic equity investment in Summit on October 5, 2026.
  • AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the announcement day.
  • The equity investment will support the continued acceleration of ivonescimab development.
  • Summit has 17 Phase III clinical studies announced, ongoing, or completed, including five Summit-sponsored global studies.
  • The company reported a GAAP net loss of $613.5 million ($0.78 per share) for the nine months ended September 30, 2026, compared to $860.4 million ($1.16 per share) in the prior year period.
  • Non-GAAP net loss for the nine months ended September 30, 2026, was $424.3 million ($0.54 per share), compared to $239.8 million ($0.33 per share) in the prior year period.